TRDA logo

TRDA
Entrada Therapeutics Inc

243
Mkt Cap
$254.66M
Volume
209.00
52W High
$16.45
52W Low
$4.93
PE Ratio
-1.68
TRDA Fundamentals
Price
$6.70
Prev Close
$6.56
Open
$6.61
50D MA
$11.49
Beta
1.54
Avg. Volume
170,933.70
EPS (Annual)
-$3.47
P/B
0.96
Rev/Employee
$167,243.42
$179.87
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire NEW YORK, May 14, 2026 NEW YORK, May 14, 2026...
News Placeholder
More News
News Placeholder
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despite positive functional improvement signals.read more...
News Placeholder
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 25,907 shares of the company's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the transaction, the insider...
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) COO Nathan Dowden Sells 15,000 Shares
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) COO Nathan Dowden sold 15,000 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating...
News Placeholder
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Trading 7.6% Higher - Should You Buy?
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Up 7.6% - What's Next...
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month High - What's Next?
Entrada Therapeutics (NASDAQ:TRDA) Hits New 52-Week High - Here's What Happened...
News Placeholder
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday
Entrada Therapeutics (NASDAQ:TRDA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-entrada-therapeutics-inc-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available